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Four cases of erysipelas-like inflammation in 
patients with metastatic melanoma treated with 
checkpoint inhibitors
Dear Editors,
Checkpoint inhibitors (CPI) can activate an antitumoral im-
mune response [1]. Immune-related adverse effects (irAE) 
occur in more than 80% of CPI-treated patients [1–3]. Rare 
irAEs are often only detected at a late stage, and fatal out-
comes have been described [4, 5]. Although monitoring and 
therapy of autoimmune side effects have led to increased saf-
ety, the range of newly discovered and described autoimmu-
ne phenomena is constantly increasing. We report on four 
 Clinical Letter patients receiving therapy with CPI for metastatic melanoma 
who developed an erysipelas-like inflammation in areas with 
cutaneous and subcutaneous metastases.
Case 1
A 71-year-old man presented with amelanotic melanoma 
metastasis (BRAF mutation V600E) with unknown primary. 
A lymph node dissection (LAD) showed that 4/22 removed 
lymph nodes had metastasized. After adjuvant radiothera-
py of the supraclavicular, infraclavicular and left axillary 
lymphatic drainage pathways (total dose 60 Gy), adjuvant 
therapy with interferon-alpha was administered. Upon pro-
gression of the disease with osseous metastases, lymph node 
metastases and a pulmonary metastasis, treatment with en-
corafenib and binimetinib was initiated. The best response to 
this regimen was stabilization of the disease with subsequent 
progression, prompting treatment with nivolumab. Within 
16 days of therapy initiation, a warm redness developed in 
the area of the cutaneous and subcutaneous metastases in the 
axilla, on the chest and on the left thoracic wall (Figure 1a). 
There was no leukocytosis, C-reactive protein was not ele-
vated, and the patient did not have fever. Histological exa-
mination of a biopsy revealed dilated lymphatic vessels and 
Figure 1 Patient 1 (a). Hematoxylin-eosin (HE)-staining of a biopsy specimen taken from the infiltrate (*localization of biopsy 
in (a)) (b). Immunohistochemistry, CD4 (red), FoxP3 (brown) (c). CD8-positive T cells (re) at the edge of an accumulation of 
melanoma cells (d). Patient 2 (e). HE-staining of a biopsy specimen taken from the infiltrate (*localization of biopsy in (e)) (f). 
Immunohistochemistry for CD4 (red), and FoxP3 (brown) (g). CD8-positive T cells (red) form a wall around a subcutaneous 
metastasis (h). Patient 3 (i). HE-staining of a tissue sample taken from the infiltrate (j). The infiltrate in (i) and (j) shows many 
eosinophils (k). Patient 4 (l).
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a perivascularly accentuated, peritumoral T cell dominated 
inflammatory response with CD4+ Tregs (CD4+/FoxP3+) and 
CD8-positive cytotoxic T cells, without infiltrating tumor 
cells. Eosinophilic granulocytes were not observed in the 
infiltrate (Figure 1b–d). The histological findings provided 
no evidence of pathogen-induced inflammation. Even with 
dabrafenib and trametinib treatment and whole-brain radi-
otherapy, the disease progressed with a fatal outcome nine 
months after initiation of nivolumab therapy.
Case 2
In a 53-year-old patient with a primary on the left shoul-
der and left axillary lymph node metastasis, adjuvant radi-
otherapy (5 Gy) and adjuvant therapy with interferon-alpha 
was terminated upon progression of multiple cutaneous 
and subcutaneous in-transit metastases. Therapy with nivo-
lumab was initiated, under which, after 41 days, a warm, 
flaring redness developed in the area of the metastases on 
the chest (Figure 1e). Histologically, a discrete infiltration of 
the tumor tissue by lymphocytes was observed, which could 
be characterized by immunohistochemistry as CD4+ Tregs 
(CD4+/FoxP3+). CD8-positive T cells appeared to wall in 
conglomerates of melanoma cells, but did not infiltrate them 
(Figure 1h). There was no infiltration by eosinophil granu-
locytes (Figure 1e–h). After three months, therapy was dis-
continued due to disease progression. The patient showed no 
response to subsequent therapies (chemotherapy with carbo-
platin and paclitaxel and electrochemotherapy). The patient 
died six months later.
Case 3
In an 80-year-old patient, disseminated metastases appeared 
on the flank almost two years after excision of the breast 
primary. Intralesional interleukin-2 therapy was discontinu-
ed after one week due to poor tolerability. Four weeks after 
termination of the IL-2 injections, therapy with pembrolizu-
mab was initiated. After 31 days, redness and hyperthermia 
developed in the area of the cutaneous and subcutaneous 
metastases (Figure 1i). A biopsy from this area showed an 
infiltrate with abundant eosinophils, both in the tumor itself 
(Figure 1k) and in its extensions (Figure 1j). The best res-
ponse to this therapy was a partial remission that lasted for 
two years. Pembrolizumab treatment was discontinued. One 
year later, there was a renewed progression of the left axillary 
lymph node metastases. Re-exposure to pembrolizumab fai-
led to achieve further remission. Figure 2 shows the percenta-
ge of eosinophilic granulocytes throughout this process.
Case 4
A 44-year-old woman was diagnosed with melanoma of the 
back of the foot, at the same time micrometastases in three 
Figure 2 Eosinophils in percent (x-axis) over time (y-axis) in Patient 3.
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inguinal lymph nodes were observed. After excision of the 
primary and LAD, adjuvant therapy with interferon-alpha 
was administered. During this time, inguinal, iliac and ob-
turatorial in-transit metastases and lymph node metastases 
arose and were operated on and adjuvantly irradiated (55 
Gy). A few months later, multiple cutaneous and subcuta-
neous metastases formed on the leg; in addition, inguinal 
lymph node metastases appeared. Combination therapy with 
dacarbazine and topical dinitrobenzene was followed by four 
rounds of immunotherapy with ipilimumab. Dabrafenib and 
trametinib were administered upon disease progression, re-
sulting in a transient response. Upon suspicion of a develo-
ping resistance, treatment was switched to pembrolizumab. 
After 28 days, a flaring, hyperthermic redness developed 
along the entire right leg (Figure 1l) with simultaneous oc-
currence of pulmonary metastases. At no time was there a 
constellation of infection. A biopsy of the erythematous area 
was not performed. Pembrolizumab therapy was supplemen-
ted by the administration of ipilimumab, resulting in a mixed 
response. The redness persisted mainly in the area of the re-
sponsive metastases. Upon progression the patient was ad-
ministered treatments with vemurafenib and cobimetinib as 
well as carboplatin and paclitaxel, none of which produced a 
response. The patient died as a result of tumor progression.
Table 1 summarizes the characteristics of all four 
patients.
Discussion
We describe erysipelas-like inflammation in four patients 
who received immunotherapy with CPI for advanced mela-
noma. All patients developed a flaring redness in the area 
of the cutaneous and subcutaneous metastases within weeks 
of therapy initiation, suggestive of a bacterial infection as 
in erysipelas or an intralymphatic spread of melanoma cells 
as in erysipelas melanomatosum. In three patients tissue 
samples of the erythematous area were taken.
Whereas erysipelas melanomatosum is defined by the 
infiltration of dermal lymphatic vessels by melanoma cells, 
erysipelas-like inflammation is understood to be clinically 
similar to erysipelas [6]. Erysipelas melanomatosum can ap-
pear long after diagnosis of the primary tumor and may be 
a sign of progression or recurrence [7, 8]. Often, the clinical 
picture is of an orange peel-like thickening of the skin. Papu-
lar and nodular changes in the sense of a cutaneous or sub-
cutaneous metastasis are often visible, histologically appea-
ring as tumor cell aggregates. An infection is often suspected 
in cases of erysipelas-like inflammation. Histologically, 
varyingly dense intratumoral or peritumoral infiltration by T 
lymphocytes of different immunophenotypes, without tumor 
cell invasion in lymphatic vessels, can be observed. The com-
position of the infiltrate excludes suppurative inflammation. 
It is important to differentiate infiltrates from cutaneous 
autoimmune side effects caused by pembrolizumab or ni-
volumab, which occurs in 15–26% of cases and which may 
appear locally rather than in a generalized manner [9, 10]. 
Histologically, such exanthema displays CD4-positive and 
melan-A-specific CD8-positive T cells in the vicinity of apop-
totic melanocytes [10].
In the patients presented here, erythema in the area of 
the cutaneous or subcutaneous metastases generally appea-
red within the first four weeks (range 16–41 days) of therapy 
with pembrolizumab or nivolumab. Three of our patients 
were men. In these, the thorax was always affected. In two 
men (Patients 1 and 2) the disease progressed rapidly. Biop-
sies of the erysipelas-like inflamed skin showed T cell infiltra-
tes, predominantly composed of regulatory T cells. Tumor 
infiltrating cytotoxic T lymphocytes were not represented. 
Where CD8-positive T cells were present, these surrounded 
the melanoma formations without infiltrating them. Patient 
3 responded to immunotherapy; in his case, the infiltrate was 
mainly eosinophilic. Corresponding eosinophilia was found 
in the blood, which became manifest and persisted following 
intralesional administration of interleukin-2. Upon recur-
rence and repeated administration of pembrolizumab, to 
which no new response was observed, an increase in eosino-
philic granulocytes ensued, though not to the same extent 
as previously seen. In Patient 4, no biopsy was taken from 
the erythematous area that developed after PD-1 blockade. 
It is noteworthy, however, that erythema occurred main-
ly in areas of responsive metastases and not in areas where 
only stabilization or progression was observed. The extent 
to which pre-therapies have an effect on the development of 
erysipelas-like inflammation is unclear. In three cases, howe-
ver, radiotherapy and therapy with interferon-alpha had been 
performed previously, and in one case a short-term intralesio-
nal application of interleukin-2 had been conducted. A recall 
phenomenon after radiotherapy seems unlikely, since the 
erythemas were found far beyond the irradiated areas. Ani-
mal experimentation has shown that a combination of radio-
therapy and PD-1 blockade can lead to tumor cell resistance, 
caused by regulatory T cell expansion [11]. In Patients 1 and 
2, this type of resistance is conceivable. The clinical picture 
of erysipelas-like inflammation under therapy with CPI may 
form the basis of various, histologically differentiable in-
flammation patterns. Immunohistological characterization 
of biopsies with infiltrate from erythematous tissue enables 
further classification and allows statements to be made on 
immunotherapy responsiveness.
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